News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
AstraZeneca Sees First Merck & Co., Inc. Payment Capped At $3.3 Billion
March 14, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 14 (Reuters) - AstraZeneca Plc said on Tuesday it believed the first option payment due to Merck & Co Inc in 2008 under a complex marketing partnership scheme between the firms was unlikely to exceed a net $3.3 billion.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
AstraZeneca
Merck & Co.
MORE ON THIS TOPIC
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Business
Deep dive: Pharma CEO compensation report
June 30, 2026
·
1 min read
·
Annalee Armstrong
Layoff Tracker
BioCryst ends all internal discovery efforts
June 30, 2026
·
64 min read
·
BioSpace Editorial Staff